Dive in
We have our own point of view on the people, technologies, and conversations that will shape the future.
Predictive and generative AI are entering many new applications. At Menlo Ventures, we are especially excited about applications for AI in drug discovery and development, specifically when new technology can directly address a major unmet need.
For those in healthcare, JPM provides the unofficial kickoff to every new year with a chance to recap the year before and inform our view on the year ahead.
Menlo Ventures has raised $1.35 billion to invest in promising technology companies leading the AI transformation.
Eleos is the leader in CareOps Automation for behavioral health and joins Menlo Ventures’ exciting portfolio of healthcare software and AI companies.
The single greatest health concern facing American kids and teens today is a crisis in mental health.
Genesis Therapeutics is pioneering AI technologies to create medicines for patients with severe and unmet medical needs.
Delfi Diagnostics has developed a test that combines ultra-low-cost sequencing and machine learning to detect cancer early.
Recursion is a breakthrough drug discovery company that combines a novel computer vision platform with deep disease biology and chemistry.
Cancer remains one of the leading causes of death in the U.S. and worldwide.
Ophelia is reinventing addiction treatment and dramatically improving access to best-in-class care with telemedicine.
In the face of a national emergency in child and adolescent mental health, urgent measures are needed to help those in need.
Attention Digital Health Founders: We are now accepting applications to attend the Digital Health Founder’s Fellowship
Riva’s mission is to improve cardiovascular disease worldwide using just the smartphones that people already have in their pockets, replacing 130-year-old blood pressure cuff technology.
Insurtech has been hot—at least seven venture-backed insurers will have gone public since the second half of 2020.
Opioid use disorder (OUD) is an epidemic that will define our generation. Roughly 90 million Americans use opioids and over 10 million misuse them.
We believe purpose-built vertical SaaS will help make drug discovery more effective and efficient and ultimately improve healthcare outcomes.
